Vertex Pharma (NASDAQ: VRTX) reported Q2 EPS of $4.52, $0.25 better than the analyst estimate of $4.27. Revenue for the quarter came in at $2.96 billion versus the consensus estimate of $2.91 billion.

GUIDANCE:

Vertex Pharma sees FY2025 revenue of $11.85-12 billion, versus the consensus of $11.94 billion.

For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.